Cannabis Report
Home > Boards > US OTC > Banking and Finance >

WestMountain Asset Management, Inc. (WASM)

Add WASM Price Alert      Hide Sticky   Hide Intro
Moderator: zen222, m1999, Quintessence, TAB78
Search This Board: 
Last Post: 7/19/2018 3:21:36 PM - Followers: 23 - Board type: Free - Posts Today: 0

Image result for cytobioscience inc
(WASM) WestMountain Asset Management, Inc. Reverse Merger with CytoBioscience, Inc. 

CytoBioscience, Inc. website: 

Share structure
Authorized Shares 50,000,000 
Outstanding Shares 11,017,402 
Float 761,750 

Shares have to be issued for the merger but they're all restricted for up to 2 years per lock-up agreement 

After the merger is finalized: 
A/S 100,000,000 
O/S 54,382,961 (Over 53 million are restricted) 
Float 761,750
8-K showing about $40 million in assets valuation with the shares that were exchanged for the merger: 

CytoBioscience's instrument is used by the FDA in its safety pharmacology studies and there isn’t any real competition. 
Our patch clamp robot is the gold standard in accurate and reliable data while saving massive amounts of time and money. 
Cytocentric's patch clamp robot. Image courtesy Cytocentric.

CytoPatch – the “hands-free” manual patch platform

Gigohm seals without enhancers
Data quality of manual 
path clamp
Can be a collection solution for analytical support
The platform 
chosen by the FDA

The Cytopatch is a robotic AI patch clamp platform designed to mimic a manual patch rig. This platform offers cell capture and sealing with quartz glass electrodes, seal resistances of 2 G? or greater without the need for seal enhancers, recordings at physiologic temperatures, and perfusion of the well for multiple concentration exposures. Because of its high data quality, flexibility, and throughput, the CytoPatch is an excellent choice for any lab wanting the performance of a manual patch clamp rig but with a much-enhanced throughput.

Routine applications include: recording ion currents in expression systems and recording ion currents and action potentials in iPS-CM or native adult cardiac myocytes. Because of its unique perfusion system, data can be obtained from difficult to record currents such as ligand activated currents and currents which desensitize rapidly.

The Cytopatch is the choice for anyone who wants the power of a manual patch clamp setup with the throughput of an automated platform at a competitive price. 

The base CytoPatch unit sells for $175,000, and CytoBioScience also sells microchips, buffers, solutions, cells, and specific types of shipping containers to researchers on a recurring basis, Garvin says. CytoBioscience, which changed its name last year, was founded in Germany and moved to San Antonio in 2015. Regulatory filings show CytoBioScience had raised about $15.8 million as of August 2016. 
They just did a $1.5 million non-dilutive offering so they're flush with cash now. ($1.53 million equity round of funding) 
From the 8K - "Each of these revenue-generating segments; instruments, consumables and contract research, is a leader in its technology and in its capacity. Having undergone years of testing, starting, restarting, and honing its development into the cutting edge it is today, the Company is experiencing accelerating revenue growth and is well-positioned to reach its potential."
Also: "The market is experiencing strong growth, driven by both regulation and rising demand for outsourced safety pharmacological work.
The company is engaged with both private and public partners globally, including the FDA."


Image result for cytobioscience inc
CytoBioscience's latest acquisition: SolubleBioScience:

CytoBioScience has 4 locations:
San Antonio, TX
New Orleans, LA
Birmingham, AL
Cologne, Germany

Contact info
Dr. James Garvin, PhD 

Company Officers and (B Of D) : 
James R. Garvin, PhD, Chief Executive Officer, President and Director 
James R. Garvin has served as the CEO, President and a Director of CytoBioscience since March 2015. Dr. Garvin has twenty-nine years of experience in working in the biotech sector and finance. His work has been recognized by the French Academy of Science and he was named one of sixteen
healthcare innovators in the state of Texas for 2017. As a former investment banker, he has worked on a number of different biotechnology acquisitions, in the US, Europe and in Israel. He has been a board member of a number of companies and currently is on the board of the Zerah Foundation which provides educational opportunities for underprivileged children in India. His international range of experiences and interests has been diverse but this has allowed him to have an outside of the box perspective that has served him well in working with companies and situations over the years. 
Dr. Garvin received his
PhD in Economic Systems from the University of New Orleans, as well as his Masters in Administration and his BA (Hons) in English and International Relations from the State University of New York, Albany 

Thomas Knott,
PhD, Chief Science Officer 
Thomas Knott,
PhD has served as the Chief Science Officer of CytoBioscience since March 2015. Dr. Thomas Knott is an innovative technology driven entrepreneur who founded Cytocentrics CCS GmbH, a high-tech scientific instrumentation and biotech company specializing in the field of ion channel electrophysiology in 2001. Dr. Knott single-handedly developed the Cytocentrics instrument for ion channel analysis, the CytoPatch™, demonstrating a more complete feature set in patch clamp capabilities than any existing manual patch clamp system (whole cell voltage clamp and current clamp, perforated patch clamp, extracellular and intracellular perfusion, temperature control, fast ligand gated ion channels, mechano-stimulation, GLP, and network capability). He has worked with three Nobel Prize-winning teams. 

Henry C. Bourg, CPA, MBA, Chief Financial Officer 
Henry C. Bourg, CPA, MBA, has served as the CFO of CytoBioscience since September 2017. Henry Bourg is an accomplished senior finance and accounting professional with over thirty years' experience with start-ups, mid-sized and multi-billion dollar global organizations. He started his career with Ernst & Young in Texas and later in Maryland and New York. While with Ernst & Young, he served primarily financial institution clients such as American General Life Insurance, Capital One 
and MBNA America Bank. In addition to his public accounting experience, Henry has served in senior finance and accounting roles with the US Government in Europe; The Shaw Group, Chicago Bridge & Iron, and Westinghouse Electric Company in Asia; Inktomi Corporation and Bookham, Inc. (now Oclaro) as well as several technology start-ups in Silicon Valley. He earned his Bachelor of Science degree in Accounting from Louisiana State University and a Master of Business Administration from Santa Clara University . 

Paul Castella,
PhD, MBA, Director 
Dr. Paul Castella is the co-founder and CEO of Santalis Pharmaceuticals, Inc. a clinical stage drug development company. Santalis is a wholly owned subsidiary of Quintis Ltd., which acquired the business in 2015, along with ViroXis Corporation (which Paul co-founded in 2008). Previously, Paul co-founded and managed a number of other life science businesses, including; CardioSpectra, Inc., which was acquired by Volcano Corporation (NASDAQ: VOLC) in December 2007; Xenotope Diagnostics, Inc., which developed the only FDA approved rapid test for Trichomonas (sold worldwide under the OSOM ® brand), the world's most prevalent non-viral sexually transmitted disease; BiO2 Medical, Inc., which developed the Angel ® Catheter, the first device indicated for the prevention of pulmonary embolism (PE) in hospitalized patients; and the San Antonio-based Targeted Technology Funds, which focus on early-stage life science investing, including an investment in CytoBioscience. 
Paul received his
PhD in cell biology and genetics from Cornell University Medical College in Manhattan, his MBA from the University of Texas at San Antonio, a BSc (Hons) in biochemistry the University of London, and has been granted ten US patents. 

Ian Clements, MSc., Director 
Ian Clements has over 25 years of commercial, corporate and business development experience in the pharmaceutical and biotechnology industries including sales and marketing, medical affairs, product and clinical development, program management as well as commercial, corporate and business development. 
Ian is the co-founder and COO of Santalis Pharmaceuticals and the co-founder and former CEO of ViroXis Corporation. Ian served for six years as Head of Commercial Operations and Corporate Development for ILEX Oncology in San Antonio where he established the new Business Development and Medical Affairs departments during the launches of Campath and
Clorfarabine. Previously, Ian has served as the Head of Oncology Product Management at Lederle labs in UK, Head of Global Oncology Product Management at the Upjohn company where he managed the global launch of Camptosar and Head of US Oncology Marketing for Novartis, managing their oncology portfolio with over $2 billion in sales and launching 3 oncology products in his tenure. 
Ian received his BS (Hons) degree in Genetics from Swansea University, UK and his MS. in Immunology from King's College, London, UK. 

Alan Dean, MBA, Director 
Alan Dean is a senior technology executive with over 40 years of experience in the technology development industry. He was employed for more than 25 years at Southern Research Institute where he became Vice-President, Commercialization, and was a principal in the first commercial spin-off companies from the Institute. As the co-founder and COO of SBS, one of the subsidiaries in the holding company he co-founded, Alan was responsible for the buyout and integration of Birmingham Polymers, Inc., a Bristol-Myers-Squibb affiliate. SBS was subsequently acquired by
Durect Corp. of California in 2001 in a transaction valued at $35 million. He has been an advisor to, and board member of, numerous technology companies, past and present. Alan is the co-founder and senior managing partner of the Targeted Technology Fund I and II, and was previously a Managing Partner of the Birmingham Technology Venture Fund. 

Shing Leong Hui, MBA, Director 
Shing Leong Hui has over thirty years' experience in the Electronics Manufacturing Services Industry. He is currently the Chairman of the Supervisory Board of Payer International Technologies GmbH where he has served since June 2002. He is the co-founder of Neutronics Electronic Industries Holding A.G., which has been subsequently acquired by Flex Ltd. (previously known as Flextronics) and was a previous Flextronics board member. Today, he is widely involved with companies which are based in Eastern Europe and China. He has a long association with Cytocentrics and was one of the original investors when it was based in Rostock, Germany. 
He has an MBA from the University of Michigan and a B.Sc in Chemical Engineering from the University of Birmingham, UK. 

Sue Lynn Hui, Director 
Sue Lynn Hui has over six years of European and Asian experience in the Pharmaceuticals, Communications
and Technology and Oil and Gas sectors. She has served as an advisory member of Payer since March 2017. She was a Manager in her previous role at A.T Kearney from 2002 to 2007. She is an advisory board member of Payer International Technologies GmbH. 
She graduated with First Class Honors in Master of Engineering in Chemical Engineering from Imperial College London, UK. 


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
WASM News: Initial Statement of Beneficial Ownership (3) 05/23/2018 05:41:12 PM
WASM News: Initial Statement of Beneficial Ownership (3) 05/21/2018 11:40:33 AM
WASM News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/16/2018 12:46:31 PM
WASM News: Initial Statement of Beneficial Ownership (3) 05/09/2018 06:50:51 PM
WASM News: Initial Statement of Beneficial Ownership (3) 05/02/2018 02:54:54 PM
PlusOneCoin Top Posts
#692   CytoBioscience's Competitors, Revenue, Number of Employees, Funding and Quintessence 07/09/18 10:03:49 PM
#599   Just a few of my favorite direct quotes zen222 06/12/18 10:41:59 AM
#708  Sticky Note CytoBioscience will be a presenter at the National Quintessence 07/12/18 03:54:07 PM
#653  Sticky Note Expecting WASM audited filings any day, per previous Money Talks 06/25/18 11:16:50 AM
#40  Sticky Note Quick WASM DD primer: zen222 05/09/18 09:17:54 PM
#745   Yes, the merger was completed on March 19, Quintessence 07/19/18 03:21:36 PM
#744   I received this from Dr. Garvin Exacly 3:06 joe117 07/19/18 03:12:37 PM
#743   I am starting to believe that the merger UkranianWolf 07/19/18 02:18:40 PM
#742   Full faith you will find it!!! HMB2010 07/17/18 02:24:38 PM
#741   There should be news coming out of the Quintessence 07/17/18 01:19:21 PM
#740   I would hope we get some news/filings this UkranianWolf 07/17/18 11:12:48 AM
#739   More impressive than transcript. Thanks,good to hear ! HMB2010 07/16/18 04:18:15 PM
#738   Found a video of the James Garvin "Texas Quintessence 07/16/18 02:35:42 PM
#737   Thanks for the updates. Going to get stockpicker1 07/16/18 02:22:30 PM
#736   Yup. Quiet now, but probably not for long... Quintessence 07/16/18 01:17:35 PM
#735   Very nice! Looking forward to filings and news Quintessence 07/16/18 01:13:44 PM
#734   with filings soon - should be fun here! HMB2010 07/16/18 01:12:28 PM
#733   Email from Dr. Garvin Dated July 10 (6 joe117 07/16/18 01:06:56 PM
#732   The conference agenda is out. Cytobioscience is Quintessence 07/15/18 10:13:07 PM
#731   I cant say this enough, Thank you Quin!!!!!!! HMB2010 07/13/18 08:26:34 PM
#730   OK, I am officially getting excited about the Quintessence 07/13/18 05:05:00 PM
#729   Looking really good today folks. People picking stockpicker1 07/13/18 01:39:37 PM
#728   Yes, I agree. With Cytobioscience mentioned (and Quintessence 07/13/18 01:16:15 PM
#727   A float of only 761,750 will tend to zen222 07/13/18 01:06:40 PM
#726   Great share structure. Pretty low OS and Quintessence 07/13/18 12:58:37 PM
#725   Some are figuring out it's no joke, no HMB2010 07/13/18 12:28:39 PM
#724   there are no shares avail. joe117 07/13/18 12:21:57 PM
#723   Yesssss !!! HMB2010 07/13/18 12:21:39 PM
#722   Nice action today! Quintessence 07/13/18 12:16:22 PM
#721   Getting exciting in here ! Thanks Quin! HMB2010 07/13/18 12:07:52 PM
#720   would you mind sharing how you arrived at joe117 07/13/18 11:41:53 AM
#719   Thanks for the link. Should bring some stockpicker1 07/13/18 11:16:30 AM
#718   Good Morning! Here is more info on Quintessence 07/13/18 09:52:55 AM
#717   And to you as well. TAB78 07/13/18 09:29:32 AM
#716   Good morning to you!! Yay it is Friday ?? stockpicker1 07/13/18 09:15:27 AM
#715   Good Morning and Happy Friday ALL TAB78 07/13/18 09:07:30 AM
#714   Good find. WASM. Money Talks 07/12/18 09:01:29 PM
#713   Nice job : ) TAB78 07/12/18 04:44:11 PM
#712   Seat belt fastened ! Bring on the HMB2010 07/12/18 04:28:29 PM
#711   You're welcome. Good things ahead. We Quintessence 07/12/18 04:27:03 PM
#710   Nice find! Thank you HMB2010 07/12/18 04:18:59 PM
#709   I give it a $15.00 - $25.00 minimum TAB78 07/12/18 04:01:51 PM
#708   CytoBioscience will be a presenter at the National Quintessence 07/12/18 03:54:07 PM
#707   Yes, that's what I am thinking too. Holding... Quintessence 07/12/18 02:59:33 PM
#706   assuming all that they say is true, 40 joe117 07/12/18 01:06:31 PM
#705   In my day job for ###,%%%, @@@@ I TAB78 07/12/18 12:44:14 PM
#704   Good day folks, hope all are well. Looks TAB78 07/11/18 11:17:59 AM
#703   Thank you Quin HMB2010 07/10/18 07:53:58 PM
#702   this has been dragging on for months! joe117 07/10/18 06:00:51 PM
#701   The change in Accountant might be a factor Quintessence 07/10/18 05:14:12 PM
#700   Always. HMB2010 07/10/18 04:41:59 PM
#699   I don't think there is a deadline. Since Quintessence 07/10/18 04:25:14 PM
#698   I just hope this won't be put on joe117 07/10/18 02:43:19 PM
#697   How late can a 10 Q be filed ? HMB2010 07/10/18 01:28:00 PM
#696   Hoping for fins/update new filing soon!! HMB2010 07/10/18 01:27:07 PM